Weekly Cytokinetics, Incorporated (NASDAQ:CYTK) Ratings

June 29, 2018 - By Sarah Holford

Cytokinetics, Incorporated (NASDAQ:CYTK) Corporate Logo
Big Money Sentiment decreased to 0.88 in Q1 2018. It has change of 0.23, from 2017Q4’s 1.11. The ratio is negative due to Cytokinetics, Incorporated positioning: 19 sold and 37 reduced. 19 funds amassed stakes and 30 increased stakes. Investors holded 38.16 million in 2017Q4 but now own 36.39 million shares or 4.65% less.
Thrivent For Lutherans holds 32,906 shs. Moreover, Great West Life Assurance Can has 0% invested in Cytokinetics, Incorporated (NASDAQ:CYTK). Tower Ltd Liability Com (Trc) stated it has 1,073 shs. Geode Cap Management Llc reported 434,120 shs stake. 16,349 are owned by State Of Alaska Department Of Revenue. State Bank Of America De reported 43,050 shs. Invesco holds 212,673 shs. Moreover, Jacobs Levy Equity Management has 0.01% invested in Cytokinetics, Incorporated (NASDAQ:CYTK) for 78,800 shs. Marshall Wace Ltd Liability Partnership invested in 0.01% or 30,600 shs. Prudential Financial stated it has 81,570 shs. California State Teachers Retirement System holds 0% in Cytokinetics, Incorporated (NASDAQ:CYTK) or 64,210 shs. Legal And General Gru Plc reported 0% in Cytokinetics, Incorporated (NASDAQ:CYTK). Bvf Incorporated Il reported 4.18% stake. Moreover, Essex Management Ltd Llc has 0.08% invested in Cytokinetics, Incorporated (NASDAQ:CYTK) for 84,690 shs. Royal National Bank Of Canada has invested 0% in Cytokinetics, Incorporated (NASDAQ:CYTK).

Cytokinetics, Incorporated registered $147,942 net activity with 0 insider buys and 5 sales since January 16, 2018. Shares for $26,850 were sold by Malik Fady Ibraham on Thursday, June 7. On Tuesday, January 16 2,709 shs were sold by McDowell Caryn Gordon, worth $24,381.

Cytokinetics, Incorporated (NASDAQ:CYTK) Ratings Coverage

In total 2 analysts cover Cytokinetics Inc (NASDAQ:CYTK). “Buy” rating has 2, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 4 are the (NASDAQ:CYTK)’s analyst reports since January 19, 2018 according to StockzIntelligence Inc. On Monday, June 18 the rating was maintained by H.C. Wainwright with “Buy”. On Friday, April 27 the firm has “Buy” rating given by H.C. Wainwright. On Friday, January 19 H.C. Wainwright maintained the shares of CYTK in report with “Buy” rating. On Wednesday, February 21 the stock of Cytokinetics, Incorporated (NASDAQ:CYTK) earned “Overweight” rating by Morgan Stanley. Listed here are Cytokinetics, Incorporated (NASDAQ:CYTK) PTs and latest ratings.

18/06/2018 Broker: H.C. Wainwright Rating: Buy New Target: $24.0000 Maintain
27/04/2018 Broker: H.C. Wainwright Rating: Buy New Target: $20.0000 Maintain
21/02/2018 Broker: Morgan Stanley Old Rating: Overweight New Rating: Overweight Old Target: $17 New Target: $18 Maintain
19/01/2018 Broker: H.C. Wainwright Rating: Buy New Target: $20.0 Maintain

Ticker’s shares touched $8.3 during the last trading session after 1.22% change.Cytokinetics, Incorporated has volume of 89,205 shares. Since June 29, 2017 CYTK has declined 37.37% and is downtrending. CYTK underperformed by 49.94% the S&P500.

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining.The company has $449.84 million market cap. The firm is developing small molecule drug candidates primarily engineered to increase muscle function and contractility.Last it reported negative earnings. The Company’s lead drug candidate is Tirasemtiv, a fast skeletal troponin activator, which is in Phase III clinical trial in patients with amyotrophic lateral sclerosis.

For more Cytokinetics, Incorporated (NASDAQ:CYTK) news posted briefly go to: Nasdaq.com, Benzinga.com, Streetinsider.com, Nasdaq.com or Nasdaq.com. The titles are as follows: “Cytokinetics Announces Data From Phase 2 Clinical Study of Reldesemtiv in Patients With Spinal Muscular Atrophy to …” posted on June 08, 2018, “Mid-Morning Market Update: Markets Open Lower; Vintage Capital To Acquire Rent-A-Center For $15/Share” on June 18, 2018, “Cytokinetics (CYTK) Announces Data From Phase 2 Clinical Study of Reldesemtiv in Patients With Spinal Muscular …” with a publish date: June 08, 2018, “Cytokinetics Announces Data From Phase 2 Clinical Study of Reldesemtiv in Patients With Spinal Muscular Atrophy …” and the last “Mid-Afternoon Market Update: Crude Oil Up Over 1%; Gevo Shares Spike Higher” with publication date: June 18, 2018.

Cytokinetics, Incorporated (NASDAQ:CYTK) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.